What are the dosing guidelines for Bromfed (brompheniramine + dextromethorphan + pseudoephedrine) in adults, children of various age groups, and infants, and what precautions should be observed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Bromfed Dosing Guidelines

For adults and children ≥12 years: 10 mL every 4 hours; children 6-11 years: 5 mL every 4 hours; children 2-5 years: 2.5 mL every 4 hours; and for infants 6 months to <2 years: physician-established dosing only—however, avoid use entirely in children <6 years due to lack of efficacy and significant safety concerns. 1

Age-Based Dosing Algorithm

Adults and Adolescents (≥12 years)

  • Dose: 10 mL (2 teaspoonfuls) every 4 hours
  • Maximum: 6 doses per 24 hours 1

School-Age Children (6 to <12 years)

  • Dose: 5 mL (1 teaspoonful) every 4 hours
  • Maximum: 6 doses per 24 hours 1

Young Children (2 to <6 years)

  • FDA-labeled dose: 2.5 mL (½ teaspoonful) every 4 hours 1
  • Critical caveat: Despite FDA labeling, avoid use in this age group based on guideline recommendations (see safety section below)

Infants (6 months to <2 years)

  • FDA label states: "Dosage to be established by a physician" 1
  • Strong recommendation: Do not use—no established efficacy and significant mortality risk (see safety section)

Critical Safety Considerations

Children Under 6 Years: Strong Evidence Against Use

The most important clinical decision point is recognizing that OTC cough and cold medications should generally be avoided in all children below 6 years of age due to lack of proven efficacy and potential toxicity. 2

The evidence supporting this recommendation is compelling:

  • Mortality data: Between 1969-2006, there were 54 fatalities associated with decongestants (pseudoephedrine, phenylephrine, ephedrine) in children ≤6 years, with 43 deaths occurring in infants <1 year 2

  • Antihistamine fatalities: During the same period, 69 deaths were associated with antihistamines including brompheniramine (9 fatalities), with 41 deaths in children <2 years 2

  • Common causes: Drug overdose and toxicity resulted from using multiple cold/cough products simultaneously, medication errors, accidental exposures, and intentional overdose 2

  • Lack of efficacy: Controlled trials demonstrate that antihistamine-decongestant combination products are not effective for upper respiratory tract infection symptoms in young children 2

FDA and Industry Response

In October 2007, major manufacturers (Wyeth, Novartis, Prestige Brands, Johnson & Johnson) voluntarily removed cough and cold medications for children <2 years from the OTC market. The FDA's advisory committees recommended against use in children <6 years 2.

Dosing Intervals and Maximum Limits

  • Frequency: Every 4 hours as needed
  • Absolute maximum: Do not exceed 6 doses in 24 hours across all age groups 1
  • Duration: Keep treatment as short as possible for acute conditions

Component-Specific Considerations

Brompheniramine Pharmacology in Children

Research shows brompheniramine in children (mean age 9.5 years) has:

  • Peak concentration at 3.2 hours
  • Terminal half-life of 12.4 hours
  • Duration of H1-blockade: 30 hours for wheals, suggesting once or twice daily dosing may be more appropriate than every 4 hours 3

This pharmacokinetic data suggests the every-4-hour dosing may lead to drug accumulation in children.

Dextromethorphan Toxicity Thresholds

  • Monitoring threshold: Ingestions of 5-7.5 mg/kg require poison center follow-up every 2 hours for 4 hours 4
  • Emergency department referral: Ingestions >7.5 mg/kg 4
  • Dose-response in children: Some evidence suggests 0.5 mg/kg may balance efficacy with adverse event avoidance 5

Pseudoephedrine Considerations

The standalone pseudoephedrine FDA label explicitly states "do not use this product in children under 6 years of age" 6, which reinforces the recommendation against Bromfed use in young children.

Common Pitfalls to Avoid

  1. Multiple product use: Parents often administer multiple OTC products simultaneously, leading to overdose—verify no other medications containing these ingredients are being used

  2. Age vs. weight dosing: The FDA label uses age-based dosing, but this creates substantial variability in actual drug exposure per kilogram 5

  3. Confusion with prescription status: While Bromfed may be available, availability does not equal appropriateness for young children

  4. Duration of use: Even when used in appropriate age groups, limit duration to the shortest time necessary for symptom control

Alternative Approaches for Young Children

For children <6 years with rhinitis symptoms, consider:

  • Second-generation antihistamines (cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine) have demonstrated good safety profiles and tolerability in young children 2
  • These agents are preferred over first-generation antihistamines like brompheniramine

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.